171 related articles for article (PubMed ID: 38773655)
1. Semimethylation is a feature of diffuse large B-cell lymphoma, and subgroups with poor prognosis are characterized by global hypomethylation and short telomere length.
Carlund O; Thörn E; Osterman P; Fors M; Dernstedt A; Forsell MNE; Erlanson M; Landfors M; Degerman S; Hultdin M
Clin Epigenetics; 2024 May; 16(1):68. PubMed ID: 38773655
[TBL] [Abstract][Full Text] [Related]
2. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.
Juskevicius D; Jucker D; Klingbiel D; Mamot C; Dirnhofer S; Tzankov A
J Hematol Oncol; 2017 Mar; 10(1):70. PubMed ID: 28302137
[TBL] [Abstract][Full Text] [Related]
3. Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients.
Wong KK; Gascoyne DM; Brown PJ; Soilleux EJ; Snell C; Chen H; Lyne L; Lawrie CH; Gascoyne RD; Pedersen LM; Møller MB; Pulford K; Murphy D; Green TM; Banham AH
Leukemia; 2014 Feb; 28(2):362-72. PubMed ID: 23884370
[TBL] [Abstract][Full Text] [Related]
4. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy.
Suzuki T; Maruyama D; Miyagi-Maeshima A; Nomoto J; Tajima K; Ito Y; Hatta S; Yuda S; Makita S; Fukuhara S; Munakata W; Suzuki T; Taniguchi H; Izutsu K; Kobayashi Y; Tobinai K
Cancer Med; 2021 Aug; 10(15):5101-5109. PubMed ID: 34105893
[TBL] [Abstract][Full Text] [Related]
7. Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma.
Voropaeva EN; Pospelova TI; Voevoda MI; Maksimov VN; Orlov YL; Seregina OB
BMC Med Genomics; 2019 Mar; 12(Suppl 2):35. PubMed ID: 30871527
[TBL] [Abstract][Full Text] [Related]
8. R-CHOP immunochemotherapy plus surgery is associated with a superior prognosis in Chinese primary intestinal diffuse large B-cell lymphoma.
Zhao F; Qin Y; Yang J; Liu P; He X; Zhou L; Zhou S; Gui L; Zhang H; Wang X; Jiang S; Zhong Q; Zhou Y; Shi Y
Asia Pac J Clin Oncol; 2020 Dec; 16(6):385-391. PubMed ID: 32779387
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
Seo S; Hong JY; Yoon S; Yoo C; Park JH; Lee JB; Park CS; Huh J; Lee Y; Kim KW; Ryu JS; Kim SJ; Kim WS; Yoon DH; Suh C
Oncotarget; 2016 Nov; 7(47):76934-76943. PubMed ID: 27764777
[TBL] [Abstract][Full Text] [Related]
10. A population-based multistate model for diffuse large B-cell lymphoma-specific mortality in older patients.
Çağlayan Ç; Goldstein JS; Ayer T; Rai A; Flowers CR
Cancer; 2019 Jun; 125(11):1837-1847. PubMed ID: 30707765
[TBL] [Abstract][Full Text] [Related]
11. Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma.
Kristensen LS; Hansen JW; Kristensen SS; Tholstrup D; Harsløf LB; Pedersen OB; De Nully Brown P; Grønbæk K
Clin Epigenetics; 2016; 8(1):95. PubMed ID: 27610206
[TBL] [Abstract][Full Text] [Related]
12. Low Expression and Promoter Hypermethylation of the Tumour Suppressor SLIT2, are Associated with Adverse Patient Outcomes in Diffuse Large B Cell Lymphoma.
Mohamed G; Talima S; Li L; Wei W; Rudzki Z; Allam RM; Simmons W; Tao Q; Murray PG
Pathol Oncol Res; 2019 Jul; 25(3):1223-1231. PubMed ID: 30739251
[TBL] [Abstract][Full Text] [Related]
13. Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.
Tzankov A; Leu N; Muenst S; Juskevicius D; Klingbiel D; Mamot C; Dirnhofer S
J Hematol Oncol; 2015 Jun; 8():70. PubMed ID: 26071053
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
Akyurek N; Uner A; Benekli M; Barista I
Cancer; 2012 Sep; 118(17):4173-83. PubMed ID: 22213394
[TBL] [Abstract][Full Text] [Related]
15. Chromosomal abnormality variation detected by G-banding is associated with prognosis of diffuse large B-cell lymphoma treated by R-CHOP-based therapy.
Mizuno Y; Tsukamoto T; Kawata E; Uoshima N; Uchiyama H; Yokota I; Maegawa S; Takimoto T; Tanba K; Matsumura-Kimoto Y; Kuwahara-Ota S; Fujibayashi Y; Yamamoto-Sugitani M; Chinen Y; Shimura Y; Horiike S; Taniwaki M; Kobayashi T; Kuroda J
Cancer Med; 2018 Mar; 7(3):655-664. PubMed ID: 29473332
[TBL] [Abstract][Full Text] [Related]
16. Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma.
Mato A; Feldman T; Zielonka T; Singavi A; Gadaletta G; Waksmundzki K; Bhattacharyya P; Chow KF; Yang X; Panush D; Agress H; Rosario M; Howlett C; Pecora A; Goy A
Leuk Lymphoma; 2013 Dec; 54(12):2606-12. PubMed ID: 23488604
[TBL] [Abstract][Full Text] [Related]
17. Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?
Abramson JS
Cancer; 2019 Sep; 125(18):3111-3120. PubMed ID: 31287161
[TBL] [Abstract][Full Text] [Related]
18. Diffuse large B-cell lymphoma in Southeast Asian cohort: expression patterns of B-cell receptor (BCR) repertoire and its linkage with molecular subtypes and response to R-CHOP therapy.
Masir N; Akhter A; Roshan TM; Florence CS; Abdul-Rahman F; Tumian NR; Kean-Chang P; Elyamany G; Shabani-Rad MT; Mansoor A
J Clin Pathol; 2019 Sep; 72(9):630-635. PubMed ID: 31189540
[TBL] [Abstract][Full Text] [Related]
19. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.
Xu-Monette ZY; Wu L; Visco C; Tai YC; Tzankov A; Liu WM; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Zhao XF; Choi WW; Zhao X; van Krieken JH; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Zhou F; Kahl BS; Winter JN; Xu W; Li J; Go RS; Li Y; Piris MA; Møller MB; Miranda RN; Abruzzo LV; Medeiros LJ; Young KH
Blood; 2012 Nov; 120(19):3986-96. PubMed ID: 22955915
[TBL] [Abstract][Full Text] [Related]
20. Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma.
Dlouhy I; Karube K; Enjuanes A; Salaverria I; Nadeu F; Ramis-Zaldivar JE; Valero JG; Rivas-Delgado A; Magnano L; Martin-García D; Pérez-Galán P; Clot G; Rovira J; Jares P; Balagué O; Giné E; Mozas P; Briones J; Sancho JM; Salar A; Mercadal S; Alcoceba M; Valera A; Campo E; López-Guillermo A
Br J Haematol; 2022 Feb; 196(3):589-598. PubMed ID: 34632572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]